FY2025 EPS Forecast for TG Therapeutics Decreased by Analyst

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings estimate for TG Therapeutics from $0.58 to $0.53 per share, while the consensus estimate is significantly lower at $0.08 per share.
• Goldman Sachs has upgraded TG Therapeutics to a "hold" rating with a price target of $37.00, amidst a consensus rating of "Moderate Buy" and an average price target of $43.80.
• In its latest quarterly earnings report, TG Therapeutics missed estimates with $0.17 EPS compared to the consensus of $0.32 and reported revenues of $141.15 million, below the anticipated $147.76 million.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of TG Therapeutics in a research note issued on Tuesday, August 5th. Cantor Fitzgerald analyst P. Agrawal now expects that the biopharmaceutical company will post earnings of $0.53 per share for the year, down from their prior estimate of $0.58. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. Cantor Fitzgerald also issued estimates for TG Therapeutics' FY2026 earnings at $1.79 EPS.

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.25.

TG Therapeutics Price Performance

TGTX traded down $1.18 during trading on Wednesday, hitting $26.71. 4,790,083 shares of the company traded hands, compared to its average volume of 2,380,766. TG Therapeutics has a 1 year low of $19.45 and a 1 year high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. The stock's 50-day simple moving average is $36.10 and its two-hundred day simple moving average is $35.95. The company has a market cap of $4.24 billion, a PE ratio of 72.19 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 27.83%. The company had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. During the same period last year, the business earned $0.04 earnings per share. The company's quarterly revenue was up 92.1% compared to the same quarter last year.

Insider Activity

In other news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director owned 228,816 shares of the company's stock, valued at $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in TG Therapeutics by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company's stock worth $126,033,000 after acquiring an additional 207,890 shares during the period. Soleus Capital Management L.P. raised its holdings in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after acquiring an additional 146,702 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock valued at $75,683,000 after acquiring an additional 345,059 shares during the last quarter. Northern Trust Corp increased its stake in TG Therapeutics by 8.6% during the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after purchasing an additional 120,785 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of TG Therapeutics by 1,809.9% in the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company's stock valued at $47,830,000 after buying an additional 1,149,526 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.